TTD | Drug: D0CG0N

Drug General Information
Drug ID	D0CG0N
Former ID	DIB004562
Drug Name	PRO-140
Synonyms	PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals
Indication	Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26]		Phase 2	[525183]
Company	Progenics Pharmaceuticals Inc
Target and Pathway
Target(s)	C-C chemokinereceptor type 5	Target Info	Antagonist	[531384]
KEGG Pathway	Cytokine-cytokine receptor interaction
	Chemokine signaling pathway
	Endocytosis
	Toxoplasmosis
	Viral carcinogenesis
NetPath Pathway	TSLP Signaling Pathway
	TCR Signaling Pathway
	IL2 Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database	IL12-mediated signaling events
Reactome	Binding and entry of HIV virion
	Chemokine receptors bind chemokines
	G alpha (i) signalling events
WikiPathways	TCR Signaling Pathway
	GPCRs, Class A Rhodopsin-like
	HIV Life Cycle
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 525183	ClinicalTrials.gov (NCT02438345) PRO 140 for Human Immunodeficiency Virus. U.S. National Institutes of Health.
Ref 531384	Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information